This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

NorLevo

HRA Pharma

Drug Names(s): levonorgestrel, SOH-075

Description: NorLevo contains levonorgestrel, a synthetic derivative of progesterone. It does not contain estrogen.

Deal Structure: Sosei and HRA Pharma
In April 2001, Sosei acquired the exclusive distribution rights to the product in Japan andAustralia from Laboratoire HRA Pharma.

ASKA and Sosei
In October 2008, Sosei announced that it has entered into a binding letter of agreement with ASKA Pharmaceuticals Co. for the commercialization of the emergency contraceptive pill SOH-075 (NorLevo).

Under the terms of the agreement, Sosei will be responsible for development and registration and ASKA for sales and marketing. A joint committee will be established to oversee all the commercialisation activities. As part of the deal structure, Sosei will receive upfront and milestone payments as well as a significant portion of net sales. ASKA will also acquire shares of Sosei.

In January 2014, Sosei agreed to transfer the Japan approved marketing authorization (MA) for NorLevo TABLETS 0.75mg (NorLevo) to ASKA Pharmaceutical Company (ASKA). Under the terms of the agreement with ASKA, Sosei...See full deal structure in Biomedtracker

Partners: Sosei Co., Ltd Aska Pharmaceutical Company Limited


NorLevo News


Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug